Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07375992

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oncology- Broadway

Baltimore, Maryland, 21287, United States

Location status: Recruiting

Location contact

Matthias Holdhoff, MD. PhD.

CONTACT

[email protected]

410-955-8837

About this study

Virtually via Zoom, all participants will meet with Music Therapists to create playlists and learn how to complete surveys measuring quality of life.

Participants will be randomly assigned, half to each arm. Arm A will interact with Music Therapists and listen to music twice a week, then independently fill out quality of life questionnaires.

Arm B will listen to music independently twice a week, then independently fill out quality of life questionnaires.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Glioblastoma (Newly Diagnosed)
  • Cognitive capacity to respond to surveys
  • Access to computer and web access
  • Ability to attend virtual music therapy sessions
  • Audibly process music
  • Proficient in English

Exclusion criteria

  • Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
  • A life expectancy of less than 6 months.
  • Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.

Treatment and study plan

Music intervention

Other

Each GBM study participant in Arm A will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be curated by a board-certified music therapist. Arm B participants will receive curated playlists of music created by a music therapist. Participants will then listen to the curated music playlists on the participant's own device twice per week.

All participants will complete a total of 16 music therapy sessions, scheduled twice per week over 8 weeks. Each session will last approximately 30 minutes.

Primary outcomes

  1. Success rate of Music Therapy intervention for GBM patients

    Time frame: 6 months

    Determine success rate of the delivery of individualized virtual music therapy (MT) in participants undergoing standard of care treatment for newly diagnosed glioblastoma.

Secondary outcomes

  1. Rate of survey completion

    Time frame: 2 years

    Rate of participants completing all surveys.

Study contacts

Contact information is provided by the study sponsor or research team.

Principal Investigator- Matthias Holdhoff, MD, PhD.

CONTACT

[email protected]

410-995-8837

Sponsors and collaborators

Lead sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Other

Collaborators

  • Keep Punching Foundation

Registry information

Official study title

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556

Acronym: MELODY

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jan 29, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.